NCT05000294 2026-06-05Atezolizumab Plus Tivozanib in Immunologically Cold Tumor TypesUniversity of FloridaPhase 1/2 Recruiting29 enrolled
NCT02834013 2026-06-03Nivolumab and Ipilimumab in Treating Patients With Rare TumorsNational Cancer Institute (NCI)Phase 2 Active not recruiting798 enrolled